Zobrazují se příspěvky se štítkemtriple negativ. Zobrazit všechny příspěvky
Zobrazují se příspěvky se štítkemtriple negativ. Zobrazit všechny příspěvky
13.03.11
06.11.10
Targeted Chemotherapy? Platinum in BRCA1-Dysfunctional Breast Cancer — JCO
Targeted Chemotherapy? Platinum in BRCA1-Dysfunctional Breast Cancer — JCO
.....
Do these data suggest that we should incorporate platinum agents into adjuvant or neoadjuvant therapy in BRCA1 carriers? No. On the basis of currently available evidence, we cannot say that there is definitive evidence of a platinum benefit in triple-negative or even BRCA1-associated breast cancer, nor can we say that there is adequate evidence to routinely incorporate platinum agents into adjuvant or neoadjuvant therapy for any identifiable subtype of breast cancer. What we can say is that this is a reasonable avenue to pursue in prospective trials, and we can feel reassured that the clinical evidence thus far fits with preclinical models. With the advent of rational approaches developed from BRCA1-associated models, which we hope will be successfully applied to sporadic basal-like breast cancer, we will finally alter the prognostic landscape for patients with this disease.
.....
Do these data suggest that we should incorporate platinum agents into adjuvant or neoadjuvant therapy in BRCA1 carriers? No. On the basis of currently available evidence, we cannot say that there is definitive evidence of a platinum benefit in triple-negative or even BRCA1-associated breast cancer, nor can we say that there is adequate evidence to routinely incorporate platinum agents into adjuvant or neoadjuvant therapy for any identifiable subtype of breast cancer. What we can say is that this is a reasonable avenue to pursue in prospective trials, and we can feel reassured that the clinical evidence thus far fits with preclinical models. With the advent of rational approaches developed from BRCA1-associated models, which we hope will be successfully applied to sporadic basal-like breast cancer, we will finally alter the prognostic landscape for patients with this disease.
24.10.10
Iniparib Improves Survival in Metastatic Triple-Negative Breast Cancer
Iniparib Improves Survival in Metastatic Triple-Negative Breast Cancer
Patients who received iniparib (Sanofi-aventis) plus gemcitabine (Gemzar; Eli Lilly) and carboplatin survived an average of almost 5 months longer than those treated with chemotherapy alone.
06.06.10
Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer - OncologySTAT
Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer - OncologySTAT:
.... "Triple-negative disease was characterized by a greater frequency of tumors >2 cm and of grade 3 tumors than observed in disease that was HER2-positive and ER and PR negative and in disease that was ER and PR positive (57% vs 49% vs 35%, respectively; P < .001). Blinded pathology examination for expression of ER, PR, HER2, and Ki-67 labeling index in the primary tumors was determined by IHC studies.....
.... "Triple-negative disease was characterized by a greater frequency of tumors >2 cm and of grade 3 tumors than observed in disease that was HER2-positive and ER and PR negative and in disease that was ER and PR positive (57% vs 49% vs 35%, respectively; P < .001). Blinded pathology examination for expression of ER, PR, HER2, and Ki-67 labeling index in the primary tumors was determined by IHC studies.....
29.12.09
Triple-negativní karcinom prsu
Pojmy
basal-like karcinom
- exprese CK 5/6, vysoká proliferace, centrální nekrózy, většinou nebývá exprese ER, PgR a HER2.
- Většina basal-like nádorů jsou triple negative,CK-5 pozitivní, s vysokou proliferací, s vysokou expresí p53,s jeho častými mutacemi
- vysoká exprese EGRF 1 a ckit.
triple negative tumory
- negativní ER, PgR, HER2 a přítomnost CK 5/6 nebo EGFR
Charakteristika triple negativních tumorů
- vychází z myoepiteliálních buněk duktů
- fenotyp (ER,PR a Her2/neu negativní) ...více zde
- a exprese vysokomolekulárních cytokeratinů např. CK5/6 a 14.
- často má atypickou medulární morfologii
- neinvazivní in situ fáze basal-like karcinomu je vzácná, má však obdobný fenotyp a umožňuje včasnou a spolehlivou diagnostiku z punkční biopsie
- téměř u 50 % případů je přítomna dysregulace EGFR
- 5–7 % všech duktálních karcinomů
- agresivnější chování a častější metastazování do plic a mozku s „vynecháním axily“, vysoký výskyt lokálních recidiv a kostních meta
- je častý u mladých žen a je nejobvyklejším morfotypem BRCA1 familiárního karcinomu
- U nádorů s mutací v genu BRCA1 je poškozena DNA reparace – především homologní rekombinace, a tím je dána senzitivita k určitým cytostatikům. In vitro studie u nádorů s mutací BRCA 1 byla prokázána senzitivita na alkylační látky, mitomycin C, platinové deriváty, etopozid a bleomycin; rezistence je popisovaná na mitotické jedy, jako jsou taxany a vinka alkaloidy
Odkazy
Přihlásit se k odběru:
Příspěvky (Atom)